SHANGHAI, March 18, 2026 – The glorious ceremony of the 2026 Forbes China Industry Development Innovator Selection came to a successful conclusion in Shanghai. Frontera Therapeutics stood out from numerous participating enterprises by virtue of its robust innovation strength in the field of rAAV gene therapy, and successfully won the prestigious 2026 Forbes China Industry Development Leader Award, marking high recognition of the company’s innovation capabilities from the judging panel and the market.

        This event was jointly launched by Forbes China and Frost & Sullivan, a world-renowned consulting firm, focusing on key national strategic sectors including biomedicine, new energy and intelligent manufacturing. Adhering to the principles of fairness, impartiality and openness, the selection adopts a rigorous multi-layer screening process involving big data analysis, expert review and on-site research, evaluating candidates across five core dimensions: technological innovation capability, commercial growth potential, industry influence, sustainable development capacity and market competitiveness. Ultimately, benchmark enterprises with both pioneering innovation spirit and leading value are selected.

        Established in 2019, Frontera Therapeutics is a global, clinical-stage rAAV gene therapy company. Since its inception, the company has been committed to delivering high-quality, affordable innovative gene therapy products to patients worldwide. To date, it has built a differentiated product pipeline with global competitive advantages, covering eight programs across three therapeutic areas, ophthalmology, cardiovascular diseases, and neurological diseases.

        Its core pipeline asset FT-002 brings curative potential to patients with X-linked retinitis pigmentosa (XLRP) globally. FT-003 offers a superior, one-time administration with long-term benefits for patients with chronic ophthalmic diseases, including neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), and is poised to benefit a large number of patients in need.

        Frontera Therapeutics owns end-to-end integrated capabilities for innovative drug R&D, manufacturing and clinical operations. It is the only company in China, and one of the few worldwide, to have established commercial-scale manufacturing capacity for rAAV gene therapies based on the Bac/sf9 expression system. Leveraging its proprietary AAVANCE^TM manufacturing technology platform and EXACTE^TM R&D technology platform, the company consistently produces high-quality rAAV gene therapy products with enhanced safety, efficacy and cost advantages. By addressing key industrial pain points, Frontera Therapeutics continues to drive the advancement of the global gene therapy industry.

        The Forbes China Industry Leader Award is not only a prestigious recognition of Frontera Therapeutics’s achievements, but also a brand-new starting point for the company’s future growth. Going forward, Frontera Therapeutics will adhere to its mission of delivering safe, effective and affordable gene therapy solutions to patients worldwide. The Company will persist in driving R&D and innovation, advancing the development of gene therapy industry, and contributing to boost China biotech industry development.